Who owns Sagimet Biosciences Inc, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
BALYASNY ASSET MANAGEMENT L.P.: 5.9% · 3,626,113 shares — BAM GP LLC: 5.9% · 3,626,113 shares — Balyasny Asset Management Holdings LP: 5.9% · 3,626,113 shares
6 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Sagimet Biosciences Inc.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Sagimet Biosciences Inc they hold. Together these 161 managers report 104.15% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. | $50.8M | 6,575,788 | 0.00% | 12.38% | June 30, 2026 |
| Balyasny Asset Management L.P. | $28M | 3,626,113 | 0.03% | 6.83% | June 30, 2026 |
159 more institutional holders behind a free account
See every manager reporting Sagimet Biosciences Inc, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 67 funds hold 15.25% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap Fund | $16.7M | 0.58% | 3.92% | April 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $14.4M | 0.00% | 3.50% | June 30, 2026 |
65 more funds behind a free account
See every fund holding Sagimet Biosciences Inc and what share of its net assets the position represents.
Sign up freeLoading...
